

Elecsys Prolactin II

cobas®

REF



SYSTEM

07027737190

07027737501

300

cobas e 402
cobas e 801

English

For use in the USA only

System information

Short name	ACN (application code number)
PRL 2	10111

Intended use

Immunoassay for the in vitro quantitative determination of prolactin in human serum and plasma.

The electrochemiluminescence immunoassay "ECLIA" is intended for use on the **cobas e** immunoassay analyzer.

Summary

Prolactin is synthesized in the anterior pituitary and is secreted in episodes. The hormone is made up of 198 amino acids and has a molecular weight of approximately 22-23 kDa. Prolactin appears in serum in three different forms. The biologically and immunologically active monomeric ("little") form predominates (approximately 80 %), 5-20 % is present as the biologically inactive dimeric ("big") form and 0.5-5 % is present as the tetrameric ("big-big") form having low biological activity.¹ The target organ for prolactin is the mammary gland, the development and differentiation of which is promoted by this hormone. High concentrations of prolactin have an inhibiting action on steroidogenesis of the ovaries and on hypophyseal gonadotropin production and secretion.

During pregnancy the concentration of prolactin rises under the influence of elevated estrogen and progesterone production. The stimulating action of prolactin on the mammary gland leads post partum to lactation.

Hyperprolactinemia (in men and women) is the main cause of fertility disorders. The determination of prolactin is utilized in the diagnosis of anovular cycles, hyperprolactinemic amenorrhea and galactorrhea, gynecomastia and azoo-spermia. Prolactin is also determined when breast cancer and pituitary tumors are suspected.²

The Elecsys Prolactin II assay uses two monoclonal antibodies specifically directed against human prolactin.

Both antibodies show a low reactivity with most forms of macroprolactin.

Test principle

Sandwich principle. Total duration of assay: 18 minutes.

- 1st incubation: 6 µL of sample and a biotinylated monoclonal prolactin-specific antibody form a first complex.
- 2nd incubation: After addition of a monoclonal prolactin-specific antibody labeled with a ruthenium complex^{a)} and streptavidin-coated microparticles, a sandwich complex is formed and becomes bound to the solid phase via interaction of biotin and streptavidin.
- The reaction mixture is aspirated into the measuring cell where the microparticles are magnetically captured onto the surface of the electrode. Unbound substances are then removed with ProCell II M. Application of a voltage to the electrode then induces chemiluminescent emission which is measured by a photomultiplier.
- Results are determined via a calibration curve which is instrument-specifically generated by 2-point calibration and a master curve provided via the **cobas** link.

a) Tris(2,2'-bipyridyl)ruthenium(II)-complex (Ru(bpy)₃²⁺)

Reagents - working solutions

The **cobas e** pack is labeled as PRL 2.

- M Streptavidin-coated microparticles, 1 bottle, 12.4 mL:
Streptavidin-coated microparticles 0.72 mg/mL; preservative.

- R1 Anti-prolactin-Ab~biotin, 1 bottle, 21.0 mL:
Biotinylated monoclonal anti-prolactin antibody (mouse) 0.7 mg/L;
phosphate buffer 50 mmol/L, pH 7.0; preservative.

- R2 Anti-prolactin-Ab~Ru(bpy)₃²⁺, 1 bottle, 21.0 mL:
Monoclonal anti-prolactin antibody (mouse) labeled with ruthenium complex 0.35 mg/L; phosphate buffer 50 mmol/L, pH 7.0; preservative.

Precautions and warnings

For in vitro diagnostic use for health care professionals. Exercise the normal precautions required for handling all laboratory reagents.

Infectious or microbial waste:

Warning: handle waste as potentially biohazardous material. Dispose of waste according to accepted laboratory instructions and procedures.

Environmental hazards:

Apply all relevant local disposal regulations to determine the safe disposal.

Safety data sheet available for professional user on request.

For USA: Caution: Federal law restricts this device to sale by or on the order of a physician.

This kit contains components classified as follows in accordance with the Regulation (EC) No. 1272/2008:



Warning

- H317 May cause an allergic skin reaction.

Prevention:

- P261 Avoid breathing dust/fume/gas/mist/vapours/spray.
P272 Contaminated work clothing should not be allowed out of the workplace.
P280 Wear protective gloves.

Response:

- P333 + P313 If skin irritation or rash occurs: Get medical advice/attention.
P362 + P364 Take off contaminated clothing and wash it before reuse.

Disposal:

- P501 Dispose of contents/container to an approved waste disposal plant.

Product safety labeling follows EU GHS guidance.

Contact phone: 1-800-428-2336

Avoid foam formation in all reagents and sample types (specimens, calibrators and controls).

Reagent handling

The reagents in the kit have been assembled into a ready-for-use unit that cannot be separated.

All information required for correct operation is available via the **cobas** link.

Storage and stability

Store at 2-8 °C.

Do not freeze.

Store the **cobas e** pack **upright** in order to ensure complete availability of the microparticles during automatic mixing prior to use.

Stability:	
unopened at 2-8 °C	up to the stated expiration date
on the analyzers	16 weeks

Elecsys Prolactin II



Specimen collection and preparation

Only the specimens listed below were tested and found acceptable. Serum collected using standard sampling tubes or tubes containing separating gel.

Li-heparin, K₂-EDTA and K₃-EDTA plasma.

Criterion: Slope 0.9-1.1 + intercept within ± 10 $\mu\text{IU/mL}$ + coefficient of correlation ≥ 0.95 .

Stable for 5 days at 20-25 °C, 14 days at 2-8 °C, 6 months at -20 °C (± 5 °C). Freeze only once.

The sample types listed were tested with a selection of sample collection tubes that were commercially available at the time of testing, i.e. not all available tubes of all manufacturers were tested. Sample collection systems from various manufacturers may contain differing materials which could affect the test results in some cases. When processing samples in primary tubes (sample collection systems), follow the instructions of the tube manufacturer.

Centrifuge samples containing precipitates before performing the assay.

Do not use heat-inactivated samples.

Do not use samples and controls stabilized with azide.

Ensure the samples and calibrators are at 20-25 °C prior to measurement.

Due to possible evaporation effects, samples and calibrators on the analyzers should be analyzed/measured within 2 hours.

Sample stability claims were established by experimental data by the manufacturer or based on reference literature and only for the temperatures/time frames as stated in the method sheet. It is the responsibility of the individual laboratory to use all available references and/or its own studies to determine specific stability criteria for its laboratory.

Materials provided

See "Reagents – working solutions" section for reagents.

Materials required (but not provided)

- [REF] 03277356190, Prolactin II CalSet, for 4 x 1.0 mL
- [REF] 11731416160, PreciControl Universal, for 4 x 3.0 mL
- [REF] 07299001190, Diluent Universal, 36 mL sample diluent
- General laboratory equipment

• **cobas e** analyzer

Additional materials for the **cobas e 402** and **cobas e 801** analyzers:

- [REF] 06908799190, ProCell II M, 2 x 2 L system solution
- [REF] 04880293190, CleanCell M, 2 x 2 L measuring cell cleaning solution
- [REF] 07485409001, Reservoir Cup, 8 cups to supply ProCell II M and CleanCell M
- [REF] 06908853190, PreClean II M, 2 x 2 L wash solution
- [REF] 05694302001, Assay Tip/Assay Cup tray, 6 magazines x 6 magazine stacks x 105 assay tips and 105 assay cups, 3 wasteliners
- [REF] 07485425001, Liquid Flow Cleaning Cup, 2 adaptor cups to supply ISE Cleaning Solution/Elecsys SysClean for Liquid Flow Cleaning Detection Unit
- [REF] 07485433001, PreWash Liquid Flow Cleaning Cup, 1 adaptor cup to supply ISE Cleaning Solution/Elecsys SysClean for Liquid Flow Cleaning PreWash Unit
- [REF] 11298500160, ISE Cleaning Solution/Elecsys SysClean, 5 x 100 mL system cleaning solution

Assay

For optimum performance of the assay follow the directions given in this document for the analyzer concerned. Refer to the appropriate operator's manual for analyzer-specific assay instructions.

Resuspension of the microparticles takes place automatically prior to use.

Place the cooled (stored at 2-8 °C) **cobas e** pack on the reagent manager. Avoid foam formation. The system automatically regulates the temperature of the reagents and the opening/closing of the **cobas e** pack.

Calibration

Traceability: This method has been standardized against the 3rd IRP WHO Reference Standard 84/500.

The predefined master curve is adapted to the analyzer using the relevant CalSet.

Calibration frequency: Calibration must be performed once per reagent lot using fresh reagent (i.e. not more than 24 hours since the **cobas e** pack was registered on the analyzer).

Calibration interval may be extended based on acceptable verification of calibration by the laboratory.

Renewed calibration is recommended as follows:

- after 12 weeks when using the same reagent lot
- after 28 days when using the same **cobas e** pack on the analyzer
- as required: e.g. quality control findings outside the defined limits

Quality control

For quality control, use PreciControl Universal.

In addition, other suitable control material can be used.

Controls for the various concentration ranges should be run individually at least once every 24 hours when the test is in use, once per **cobas e** pack, and following each calibration.

The control intervals and limits should be adapted to each laboratory's individual requirements. Values obtained should fall within the defined limits. Each laboratory should establish corrective measures to be taken if values fall outside the defined limits.

If necessary, repeat the measurement of the samples concerned.

Follow the applicable government regulations and local guidelines for quality control.

Calculation

The analyzer automatically calculates the analyte concentration of each sample (either in $\mu\text{IU/mL}$, ng/mL or in mIU/L).

$$\begin{aligned} \text{Conversion factors:} \quad & \mu\text{IU/mL (mIU/L)} \times 0.047 = \text{ng/mL} \\ & \text{ng/mL} \times 21.2 = \mu\text{IU/mL (mIU/L)} \end{aligned}$$

Limitations - interference

The effect of the following endogenous substances and pharmaceutical compounds on assay performance was tested. Interferences were tested up to the listed concentrations and no impact on results was observed.

Endogenous substances

Compound	Concentration tested
Bilirubin	$\leq 513 \mu\text{mol/L}$ or $\leq 30 \text{ mg/dL}$
Hemoglobin	$\leq 0.932 \text{ mmol/L}$ or $\leq 1500 \text{ mg/dL}$
Intralipid	$\leq 1500 \text{ mg/dL}$
Biotin	$\leq 164 \text{ nmol/L}$ or $\leq 40 \text{ ng/mL}$
Rheumatoid factors	$\leq 1100 \text{ IU/mL}$

Criterion: For concentrations of 2-50 $\mu\text{IU/mL}$ the deviation is $\leq \pm 10 \mu\text{IU/mL}$. For concentrations > 50-100 $\mu\text{IU/mL}$ the deviation is $\pm 20 \%$. For concentrations > 100 $\mu\text{IU/mL}$ the deviation is $\pm 15 \%$.

Samples should not be taken from patients receiving therapy with high biotin doses (i.e. > 5 mg/day) until at least 8 hours following the last biotin administration.

There is no high-dose hook effect at prolactin concentrations up to 270000 $\mu\text{IU/mL}$ (12690 ng/mL).

Pharmaceutical substances

In vitro tests were performed on 16 commonly used pharmaceuticals. No interference with the assay was found.

In rare cases, interference due to extremely high titers of antibodies to analyte-specific antibodies, streptavidin or ruthenium can occur. These effects are minimized by suitable test design.

When determining prolactin it should be remembered that the measured concentration is dependent upon when the blood sample was taken, since the secretion of prolactin occurs in episodes and is also subject to a 24-hour cycle.^{3,4}

Elecsys Prolactin II

In addition, elevated serum prolactin concentrations are caused by a number of pharmaceuticals (e.g. dibenzodiazepines, phenothiazine), TRH and estrogen.^{5,6,7}

The release of prolactin is inhibited by dopamine, L-dopa and ergotamine derivatives.

A number of publications report the presence of macroprolactin in the serum of female patients with various endocrinological diseases or during pregnancy. Differing degrees of detection of the serum macroprolactins relative to monomeric prolactin (22-23 kDa) by various immunoassays have also been described. This could lead to a false diagnosis of hyperprolactinemia depending on the immunoassay used.⁸

In case of implausible high prolactin values a precipitation by polyethylene glycol (PEG) is recommended in order to estimate the amount of the biological active monomeric prolactin.^{9,10,11,12,13,14,15,16,17,18}

See section "Sample pretreatment by polyethylene glycol (PEG) precipitation" for further details.

For diagnostic purposes, the results should always be assessed in conjunction with the patient's medical history, clinical examination and other findings.

Limits and ranges

Measuring range

2-10000 µIU/mL or 0.094-470 ng/mL (defined by the Limit of Detection and the maximum of the master curve). Values below the Limit of Detection are reported as < 2 µIU/mL or < 0.094 ng/mL. Values above the measuring range are reported as > 10000 µIU/mL or > 470 ng/mL (or up to 100000 µIU/mL or 4700 ng/mL for 10-fold diluted samples).

Lower limits of measurement

Limit of Blank, Limit of Detection and Limit of Quantitation

Limit of Blank = 1 µIU/mL (0.047 ng/mL)

Limit of Detection = 2 µIU/mL (0.094 ng/mL)

Limit of Quantitation = 20 µIU/mL (0.940 ng/mL)

The Limit of Blank, Limit of Detection and Limit of Quantitation were determined in accordance with the CLSI (Clinical and Laboratory Standards Institute) EP17-A2 requirements.

The Limit of Blank is the 95th percentile value from $n \geq 60$ measurements of analyte-free samples over several independent series. The Limit of Blank corresponds to the concentration below which analyte-free samples are found with a probability of 95 %.

The Limit of Detection is determined based on the Limit of Blank and the standard deviation of low concentration samples. The Limit of Detection corresponds to the lowest analyte concentration which can be detected (value above the Limit of Blank with a probability of 95 %).

The Limit of Quantitation is the lowest analyte concentration that can be reproducibly measured with an intermediate precision CV of ≤ 20 %.

Dilution

Samples with prolactin concentrations above the measuring range can be diluted with Diluent Universal. The recommended dilution is 1:10 (either automatically by the analyzers or manually). The concentration of the diluted sample must be ≥ 50 µIU/mL or ≥ 2.40 ng/mL.

After manual dilution, multiply the result by the dilution factor.

After dilution by the analyzers, the software automatically takes the dilution into account when calculating the sample concentration.

Expected values

A study with the Elecsys Prolactin II assay was performed using samples from 300 apparently healthy blood donors. The following results were obtained:

		Percentiles			
		50 th	2.5-97.5 th	50 th	2.5-97.5 th
		N	µIU/mL	ng/mL	
Men	102	155	86-324	7.30	4.04-15.2
Women (not-pregnant)	198	225	102-496	10.6	4.79-23.3

Each laboratory should investigate the transferability of the expected values to its own patient population and if necessary determine its own reference ranges.

Moreover, it should be remembered that the measured concentration is dependent upon when the blood sample was taken, since the secretion of prolactin occurs in episodes and is also subject to a 24-hour cycle.^{3,4}

Specific performance data

Representative performance data on the analyzers are given below. Results obtained in individual laboratories may differ.

Precision

Precision was determined using Elecsys reagents, pooled human sera and controls in a protocol (EP05-A3) of the CLSI (Clinical and Laboratory Standards Institute): 2 runs per day in duplicate each for 21 days ($n = 84$). The following results were obtained:

cobas e 402 and cobas e 801 analyzers								
Sample			Repeatability			Intermediate precision		
	Mean		SD		CV	SD		CV
	µIU/mL	ng/mL	µIU/mL	ng/mL	%	µIU/mL	ng/mL	%
HS ^{b)} 1	10.5	0.494	0.269	0.013	2.6	0.313	0.015	3.0
HS 2	73.6	3.46	2.26	0.106	3.1	2.81	0.132	3.8
HS 3	598	28.1	10.6	0.498	1.8	15.9	0.747	2.7
HS 4	2017	94.8	47.4	2.23	2.4	58.6	2.75	2.9
HS 5	5612	264	115	5.41	2.1	162	7.61	2.9
HS 6	8343	392	178	8.37	2.1	295	13.9	3.5
PC ^{c)} Universal1	253	11.9	5.13	0.241	2.0	6.62	0.311	2.6
PC Universal2	874	41.1	17.5	0.823	2.0	38.0	1.79	4.4

b) HS = human serum

c) PC = PreciControl

Method comparison

A comparison of the Elecsys Prolactin II assay on the **cobas e 801** analyzer (y) with the Elecsys Prolactin II assay on the **cobas e 601** analyzer (x) using clinical samples gave the following correlations (µIU/mL):
Number of samples measured: 132

Passing/Bablok ¹⁹	Linear regression
$y = 1.02x - 0.238$	$y = 1.01x + 8.64$
$r = 0.985$	$r = 0.999$

The sample concentrations were between 2.63 and 9693 µIU/mL.

Analytical specificity

The monoclonal antibodies used are highly specific against prolactin. No cross reaction with hGH, hCG, hPL, TSH, FSH and LH has been observed.

Sample pretreatment by polyethylene glycol (PEG) precipitation

Test principle

Macroprolactin and oligomers can be precipitated by using a 25 % aqueous PEG solution (ratio 1+1). After centrifugation, the supernatant containing monomeric prolactin is used in the Elecsys Prolactin II assay in the same way as a native sample. The dilution effect which occurs during sample pretreatment and the coprecipitation of monomeric prolactin must be taken into consideration.

Reagents (not provided)

- Polyethylene glycol 6000 (e.g. available from Serva, Cat. No. 33137)
- Sigma PEG 6000 (e.g. available from Sigma-Aldrich CAS 25322-68-3)
- Distilled or deionized water

Precautions and warnings

See instructions provided by the manufacturer of the polyethylene glycol 6000.

Elecsys Prolactin II



Reagent handling

To prepare a 25 % PEG solution, dissolve 25 g polyethylene glycol 6000 in approximately 60 mL of distilled or deionized water at 18-25 °C (magnetic stirrer, 15 minutes) and fill up to 100 mL.

Storage and stability

Store the original substance according to the instructions of the manufacturer.

Store the 25 % PEG solution at 20-25 °C.

Stability of the solution: 7 days.

Materials required (but not provided)

- Magnetic stirrer
- Rotating shaker (vortex)
- Centrifuge (1500 g to 10000 g)

Assay

Sample pretreatment (18-25 °C):

- Mix appropriate volume of sample (at least 180 µL) with PEG solution at a ratio of 1+1
- Mix well for approximately 10 seconds in a rotating shaker (vortex)
- Centrifuge for 5 minutes between 1500 g and 10000 g (within 1-30 minutes)

Analyze the supernatant in the same way as the native samples.

Calculation

Approximately 14 % (range: 0-40 %) of monomeric prolactin is coprecipitated by PEG.¹⁴ The dilution effect which occurs during PEG treatment and the coprecipitation of monomeric prolactin must be taken into consideration when calculating the results.

After precipitation by PEG each laboratory should investigate the transferability of the expected values to its own patient population and if necessary determine its own reference ranges.

References

- 1 Smith CR, Norman MR. Prolactin and growth hormone: molecular heterogeneity and measurement in serum. *Ann Clin Biochem* 1990;27:542-550.
- 2 Runnebaum B, Rabe T. Gynäkologische Endokrinologie und Fortpflanzungsmedizin Springer Verlag 1994. Band 1:21,124-126,179-181,613, Band 2:412-417,436. ISBN 3-540-57345-3, ISBN 3-540-57347-X.
- 3 Roelfsema F, Pijl H, Keenan DM, et al. Prolactin secretion in healthy adults is determined by gender, age and body mass index. *PLoS ONE* 2012;7(2):e31305.
- 4 Aitkenhead H, Heales SJ. Establishment of paediatric age-related reference intervals for serum prolactin to aid in the diagnosis of neurometabolic conditions affecting dopamine metabolism. *Ann Clin Biochem* 2013;50:156-158.
- 5 Frantz AG. Prolactin. *New Engl J Med* 1978;298:201-207.
- 6 Müller EE, Locatelli V, Cella S, et al. Prolactin-lowering and -releasing drugs. Mechanisms of action and therapeutic applications. *Drugs* 1983;25:399-432.
- 7 Pontiroli AE, Falsetti L, Bottazzo G. Clinical, endocrine, roentgenographic, and immune characterization of hyperprolactinemic women. *Int J Fertil* 1987;32:81-85.
- 8 Fahie-Wilson M, Smith TP. Determination of prolactin: The macroprolactin problem. *Best Pract Res Clin Endocrinol Metab* 2013;27:725-742.
- 9 Fahie-Wilson MN, Soule SG. Macroprolactinaemia: contribution to hyperprolactinaemia in a district general hospital and evaluation of a screening test based on precipitation with polyethylene glycol. *Ann Clin Biochem* 1997;34:252-258.
- 10 Fahie-Wilson MN, Brunsden P, Surrey J, et al. Macroprolactin and the Roche Elecsys Prolactin assay: characteristics of the reaction and detection by precipitation with polyethylene glycol. *Clin Chem* 2000;46:1993-1995.

- 11 Leslie H, Courtney CH, Bell PM, et al. Laboratory and clinical experience in 55 patients with macroprolactinemia identified by a simple polyethylene glycol precipitation method. *J Clin Endocrinol Metab* 2001;86:2743-2746.
- 12 Gilson, Schmit P, Thix J, et al. Prolactin results for samples containing macroprolactin are method and sample dependent. *Clin Chem* 2001;47:331-333.
- 13 Schneider W, Marcovitz S, Al-Shammari S, et al. Reactivity of macroprolactin in common automated immunoassays. *Clin Biochem* 2001;34:469-473.
- 14 Sapin R, Gasser F, Grucker D. Free prolactin determinations in hyperprolactinemic men with suspicion of macroprolactinemia. *Clin Chim Acta* 2002;316:33-41.
- 15 Gibney J, Smith TP, McKenna TJ. Clinical relevance of macroprolactin. *Clin Endocrinol* 2005;62:633-643.
- 16 Fahie-Wilson MN, John R, Ellis AR. Macroprolactin; high molecular mass forms of circulating prolactin. *Ann Clin Biochem* 2005;42:175-192.
- 17 Suliman AM, Smith TP, Gibney J, et al. Frequent misdiagnosis and mismanagement of hyperprolactinemic patients before the introduction of macroprolactin screening: application of a new strict laboratory definition of macroprolactinemia. *Clin Chem* 2003;49(9):1504-1509.
- 18 Gibney J, Smith TP, McKenna TJ. The impact of clinical practice of routine screening for macroprolactin. *J Clin Endocrinol Metab* 2005;90:3927-3932.
- 19 Bablok W, Passing H, Bender R, et al. A general regression procedure for method transformation. Application of linear regression procedures for method comparison studies in clinical chemistry, Part III. *J Clin Chem Clin Biochem* 1988 Nov;26(11):783-790.

For further information, please refer to the appropriate operator's manual for the analyzer concerned, the respective application sheets and the Method Sheets of all necessary components (if available in your country).

Any serious incident that has occurred in relation to the device shall be reported to the manufacturer and the competent authority of the Member State in which the user and/or the patient is established.

Symbols

Roche Diagnostics uses the following symbols and signs in addition to those listed in the ISO 15223-1 standard (for USA: see dialog.roche.com for definition of symbols used):

	Contents of kit
	Analyzers/Instruments on which reagents can be used
	Reagent
	Calibrator
	Volume for reconstitution
	Global Trade Item Number

FOR US CUSTOMERS ONLY: LIMITED WARRANTY

Roche Diagnostics warrants that this product will meet the specifications stated in the labeling when used in accordance with such labeling and will be free from defects in material and workmanship until the expiration date printed on the label. THIS LIMITED WARRANTY IS IN LIEU OF ANY OTHER WARRANTY, EXPRESS OR IMPLIED, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR PARTICULAR PURPOSE. IN NO EVENT SHALL ROCHE DIAGNOSTICS BE LIABLE FOR INCIDENTAL, INDIRECT, SPECIAL OR CONSEQUENTIAL DAMAGES.

COBAS, COBAS E, ELECSYS and PRECICONTROL are trademarks of Roche. INTRALIPID is a trademark of Fresenius Kabi AB.

All other product names and trademarks are the property of their respective owners.

Additions, deletions or changes are indicated by a change bar in the margin.

© 2022, Roche Diagnostics

Elecsys Prolactin II

cobas[®]



Roche Diagnostics GmbH, Sandhofer Strasse 116, D-68305 Mannheim
www.roche.com



Distribution in USA by:
Roche Diagnostics, Indianapolis, IN
US Customer Technical Support 1-800-428-2336